Exponent Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Exponent de 8.4% y 7.9% por año respectivamente. Se prevé que el BPA crezca en un 8.9% al año. Se espera que la rentabilidad financiera sea de 29.7% en 3 años.
Información clave
8.4%
Tasa de crecimiento de los beneficios
8.90%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Professional Services | 15.4% |
| Tasa de crecimiento de los ingresos | 7.9% |
| Rentabilidad financiera futura | 29.71% |
| Cobertura de analistas | Low |
| Última actualización | 01 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • May 04
Exponent: Rising Demand And A Reasonable Valuation Make It A Buy
Summary Exponent is a market leader in scientific and engineering consulting, boasting a 13-year dividend growth streak and a fortress balance sheet. EXPO’s fiscal 2026 outlook signals rising top and bottom lines, with AI-related demand driving proactive and reactive service growth. The stock trades at ~26.5x FY26E EPS, well below its 5-year average, suggesting undervaluation with a fair value estimate of $73.80 versus a ~$65 share price. Dividend safety is outstanding, supported by a conservative ~50% payout ratio, robust free cash flow, and no debt. Read the full article on Seeking Alpha
Actualización del análisis • May 03
EXPO: AI Failure Analysis And Buybacks Will Support Higher Earnings Quality
Analysts have adjusted their view on Exponent with a modest change to the price target in the $5 range, reflecting updated assumptions on growth, profitability and a slightly higher future P/E multiple informed by recent mixed revisions from JPMorgan and UBS. Analyst Commentary Recent commentary around Exponent highlights a mix of caution and optimism, with price targets adjusted within a narrow range and opinions split on the risk and reward at current levels.Actualización del análisis • Apr 18
EXPO: AI Failure Analysis Demand Will Support Higher Earnings Quality
Analysts have adjusted the 12 month price target on Exponent to $95 from $90, reflecting updated assumptions around revenue growth, profit margins, and the P/E multiple they are willing to apply to future earnings. Analyst Commentary Recent Street research on Exponent has centered on how much investors are willing to pay for the company’s future earnings, with price targets adjusted as analysts revisit revenue assumptions, profit margins, and the P/E multiple.
Actualización del análisis • Apr 04
EXPO: AI Failure Analysis Work Will Sustain Premium P/E And Shareholder Returns
Analysts have trimmed their average price target for Exponent by $1.67 to reflect slightly lower fair value and profit margin assumptions, while still applying a relatively high future P/E multiple informed by recent mixed price target moves from JPMorgan and UBS. Analyst Commentary Recent Street research on Exponent reflects a mix of optimism about the business model and caution around valuation and near term execution, which is why price targets have moved in both directions.Actualización del análisis • Mar 21
EXPO: AI Failure Analysis Work Will Support Margins And Shareholder Returns
Analysts have lifted their 12 month price target on Exponent by about $6 to around $92. This reflects updated expectations around revenue, margins and a slightly lower future P/E multiple following recent research updates from major firms.
Actualización del análisis • Mar 07
EXPO: Buybacks And Dividend Increases Will Support Future Shareholder Returns
Analysts nudged their price target on Exponent higher by $4, citing slightly firmer growth and margin assumptions, along with a modestly lower future P/E outlook as key supports for the revised view. Analyst Commentary Recent research coverage around Exponent has centered on how much investors should be willing to pay for the company relative to its growth and margin profile.Actualización del análisis • Feb 20
EXPO: Raised UBS Target And Buybacks Will Support Higher Future P/E
Analysts have raised their price target on Exponent by $4 to $85, citing updated assumptions that include slightly lower revenue growth, a modestly higher discount rate, improved profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent Street research around Exponent highlights a mix of optimism and restraint, with the latest published work focusing on valuation inputs, growth expectations, and how much investors are willing to pay for the stock through the P/E multiple.Artículo de análisis • Feb 09
Exponent (NASDAQ:EXPO) Is Increasing Its Dividend To $0.31
The board of Exponent, Inc. ( NASDAQ:EXPO ) has announced that the dividend on 20th of March will be increased to...Actualización del análisis • Feb 06
EXPO: Bullish JPMorgan Initiation Will Support Confidence In Updated Fair Value Estimate
Analysts have raised their fair value estimate for Exponent from US$76.00 to US$81.00, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple in light of recent bullish Street research. Analyst Commentary Recent Street research, including a new bullish view from JPMorgan, has put more attention on how Exponent is priced and what could get in the way of the updated fair value estimate of US$81.00.Actualización del análisis • Jan 23
EXPO: AI Failure Analysis Work Will Offset Automation Headwind Risks
Analysts have trimmed their price target on Exponent to US$90 from US$100, citing both the potential for increased AI driven failure analysis work and the offsetting risk that greater automation could reduce billable hours in consulting. Analyst Commentary Recent research points to a more balanced view on Exponent, with the reduced US$90 price target reflecting both potential upside from AI driven work and execution risks around automation in core consulting practices.Actualización del análisis • Jan 09
EXPO: AI Failure Analysis Demand Will Support Future Consulting Engagements
Analysts have reduced their fair value estimate for Exponent to $90 from $100, citing a lower assumed future P/E multiple as they weigh the potential for AI-driven demand for failure analysis work against the risk that automation could reduce billable hours across the consulting sector. Analyst Commentary Recent commentary from bullish analysts centers on how AI adoption could shape Exponent's long term opportunity set, even as they factor in the risk that automation may cap billable hours across the consulting sector.Artículo de análisis • Jan 08
What Exponent, Inc.'s (NASDAQ:EXPO) P/E Is Not Telling You
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 34.9x might make it look like a strong sell...Actualización del análisis • Dec 16
EXPO: AI Failure Analysis Demand Will Outweigh Automation Efficiency Headwinds
Analysts have nudged their fair value estimate for Exponent higher to approximately $85.50 from $83.00 per share, citing the potential for AI driven demand in complex failure analysis work, while acknowledging that automation related efficiency gains could temper billable hours across the consulting industry. Analyst Commentary Bullish analysts highlight that the revised target still implies meaningful upside from current levels, even after a modest trim.Actualización del análisis • Dec 01
EXPO: AI-Driven Demand Will Drive Future Engagements Despite Automation Headwinds
Analysts have revised Exponent's price target downward by $10 to $90 per share, citing potential opportunities from AI-driven engagements as well as industry headwinds related to automation efficiencies. Analyst Commentary Following the recent revision to Exponent's price target, analysts have highlighted both opportunities and risks facing the company in today's evolving market landscape.Actualización del análisis • Nov 17
EXPO: AI-Driven Client Demand Will Offset Automation Concerns In Consulting
Exponent’s analyst price target has been reduced by $10 to $90, as analysts cite ongoing automation concerns that could impact the consulting sector. They also note potential opportunities from increased AI-driven client demand.Artículo de análisis • Nov 02
Exponent, Inc. Just Beat EPS By 8.5%: Here's What Analysts Think Will Happen Next
A week ago, Exponent, Inc. ( NASDAQ:EXPO ) came out with a strong set of third-quarter numbers that could potentially...Actualización del análisis • Nov 02
EXPO: Increased Buyback Will Drive Shareholder Returns In Coming Quarters
Narrative Update: Exponent Analyst Price Target Adjustment Analysts have lowered their price target for Exponent from $88 to $83. This change reflects updated expectations for revenue growth and profitability margins moving forward.Artículo de análisis • Oct 06
Returns On Capital At Exponent (NASDAQ:EXPO) Have Stalled
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Artículo de análisis • Jul 30
A Look At The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$63.97 based on 2 Stage Free Cash Flow to Equity Exponent's US$70.44...Artículo de análisis • Jul 14
When Should You Buy Exponent, Inc. (NASDAQ:EXPO)?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it received a lot of attention from a substantial...Artículo de análisis • Jun 28
Exponent (NASDAQ:EXPO) Knows How To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Artículo de análisis • May 27
Subdued Growth No Barrier To Exponent, Inc.'s (NASDAQ:EXPO) Price
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 36.7x might make it look like a strong sell...Artículo de análisis • Apr 06
Is Exponent, Inc. (NASDAQ:EXPO) Potentially Undervalued?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it saw significant share price movement during...Artículo de análisis • Mar 22
Return Trends At Exponent (NASDAQ:EXPO) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Mar 10
Exponent: A Unique Dividend Contender That Is Valued At A Premium
Summary Exponent Inc. is a market leader in scientific and engineering consulting, with a 13-year dividend growth streak and a solid balance sheet. Despite strong revenue and earnings growth, the valuation is at a premium, making Exponent a hold. The company's competitive advantages include its reputation, technical expertise, and long-term client relationships, ensuring continued market leadership. Exponent's dividend safety is excellent, supported by a conservative payout ratio and robust free cash flow, but the current valuation is a concern. Read the full article on Seeking AlphaArtículo de análisis • Feb 13
Exponent's (NASDAQ:EXPO) Shareholders Will Receive A Bigger Dividend Than Last Year
Exponent, Inc.'s ( NASDAQ:EXPO ) dividend will be increasing from last year's payment of the same period to $0.30 on...Artículo de análisis • Jan 30
Exponent, Inc.'s (NASDAQ:EXPO) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights The projected fair value for Exponent is US$122 based on 2 Stage Free Cash Flow to Equity Exponent is...Artículo de análisis • Dec 28
Risks To Shareholder Returns Are Elevated At These Prices For Exponent, Inc. (NASDAQ:EXPO)
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 42.7x might make it look like a strong sell...Artículo de análisis • Dec 10
Here's What To Make Of Exponent's (NASDAQ:EXPO) Decelerating Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Artículo de análisis • Nov 08
Exponent's (NASDAQ:EXPO) Earnings Seem To Be Promising
Despite posting healthy earnings, Exponent, Inc.'s ( NASDAQ:EXPO ) stock has been quite weak. Along with the solid...Artículo de análisis • Oct 13
Estimating The Intrinsic Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$114 based on 2 Stage Free Cash Flow to Equity Current share price of...
Nuevo análisis • Aug 29
Operational Efficiency And Tactical Investments Set To Propel Future Profitability And Revenue Growth
Exponent's strategic management and operational efficiency improvements are poised to enhance future profitability and earnings potential.Artículo de análisis • Aug 20
Exponent, Inc.'s (NASDAQ:EXPO) Share Price Not Quite Adding Up
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 51.1x might make it look like a strong sell...Artículo de análisis • Jul 28
Exponent, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, Exponent, Inc. ( NASDAQ:EXPO ) recently reported its second-quarter numbers. Revenues were US$132m...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 667 | 138 | N/A | N/A | 1 |
| 12/31/2027 | 648 | 125 | 209 | 173 | 4 |
| 12/31/2026 | 597 | 113 | 185 | 144 | 4 |
| 4/3/2026 | 551 | 109 | 113 | 123 | N/A |
| 1/2/2026 | 537 | 106 | 122 | 132 | N/A |
| 10/3/2025 | 531 | 105 | 123 | 132 | N/A |
| 7/4/2025 | 519 | 103 | 121 | 129 | N/A |
| 4/4/2025 | 519 | 106 | 134 | 141 | N/A |
| 1/3/2025 | 518 | 109 | 138 | 145 | N/A |
| 9/27/2024 | 509 | 106 | 154 | 160 | N/A |
| 6/28/2024 | 508 | 105 | 144 | 152 | N/A |
| 3/29/2024 | 506 | 101 | 132 | 144 | N/A |
| 12/29/2023 | 497 | 100 | 111 | 127 | N/A |
| 9/29/2023 | 496 | 102 | 79 | 97 | N/A |
| 6/30/2023 | 486 | 102 | 87 | 104 | N/A |
| 3/31/2023 | 475 | 102 | 78 | 93 | N/A |
| 12/30/2022 | 464 | 102 | 82 | 94 | N/A |
| 9/30/2022 | 456 | 100 | 97 | 107 | N/A |
| 7/1/2022 | 449 | 100 | 94 | 103 | N/A |
| 4/1/2022 | 443 | 100 | 110 | 117 | N/A |
| 12/31/2021 | 435 | 101 | 118 | 125 | N/A |
| 10/1/2021 | 428 | 103 | 105 | 111 | N/A |
| 7/2/2021 | 413 | 96 | 108 | 115 | N/A |
| 4/2/2021 | 388 | 87 | 112 | 118 | N/A |
| 1/1/2021 | 378 | 83 | 98 | 103 | N/A |
| 10/2/2020 | 383 | 80 | 108 | 118 | N/A |
| 7/3/2020 | 385 | 81 | 104 | 117 | N/A |
| 4/3/2020 | 398 | 86 | 88 | 106 | N/A |
| 1/3/2020 | 391 | 82 | N/A | 108 | N/A |
| 9/27/2019 | 374 | 79 | N/A | 97 | N/A |
| 6/28/2019 | 368 | 77 | N/A | 88 | N/A |
| 3/29/2019 | 357 | 75 | N/A | 75 | N/A |
| 12/28/2018 | 355 | 72 | N/A | 91 | N/A |
| 9/28/2018 | 352 | 53 | N/A | 88 | N/A |
| 6/29/2018 | 346 | 50 | N/A | 79 | N/A |
| 3/30/2018 | 340 | 45 | N/A | 73 | N/A |
| 12/29/2017 | 330 | 41 | N/A | 68 | N/A |
| 9/29/2017 | 320 | 55 | N/A | 57 | N/A |
| 6/30/2017 | 312 | 52 | N/A | 70 | N/A |
| 3/31/2017 | 301 | 49 | N/A | 65 | N/A |
| 12/30/2016 | 299 | 47 | N/A | 67 | N/A |
| 9/30/2016 | 296 | 47 | N/A | 63 | N/A |
| 7/1/2016 | 297 | 47 | N/A | 60 | N/A |
| 4/1/2016 | 299 | 49 | N/A | 59 | N/A |
| 1/1/2016 | 296 | 44 | N/A | 60 | N/A |
| 10/2/2015 | 296 | 43 | N/A | 56 | N/A |
| 7/3/2015 | 295 | 42 | N/A | 52 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (8.4% al año) de EXPO es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (8.4% al año) de EXPO crezcan menos que el mercado US (16.7% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de EXPO crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (7.9% al año) de EXPO crezcan más despacio que el mercado de US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 7.9% al año) de EXPO crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de EXPO sea alta dentro de 3 años (29.7%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/11 04:51 |
| Precio de las acciones al final del día | 2026/05/11 00:00 |
| Beneficios | 2026/04/03 |
| Ingresos anuales | 2026/01/02 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Exponent, Inc. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joseph Foresi | Brean Capital Historical (Janney Montgomery) |
| Alexis Huseby | D.A. Davidson & Co. |
| Tomohiko Sano | J.P. Morgan |